Published in Neuropsychopharmacology on March 10, 2010
Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology (2010) 2.97
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet (2011) 2.10
A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology (2011) 1.72
CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) (2011) 1.57
Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation (2011) 1.56
Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry (2014) 1.54
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry (2012) 1.47
Cognitive mechanisms of treatment in depression. Neuropsychopharmacology (2011) 1.43
Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42
High-frequency brain activity and muscle artifacts in MEG/EEG: a review and recommendations. Front Hum Neurosci (2013) 1.40
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39
Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs (2012) 1.38
Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther (2011) 1.34
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions. Proc Natl Acad Sci U S A (2015) 1.23
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
Human biomarkers of rapid antidepressant effects. Biol Psychiatry (2013) 1.09
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry (2012) 1.09
Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol (2014) 1.06
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci (2015) 1.04
A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci (2012) 1.02
Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry (2013) 1.02
Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans. J Neurosci (2015) 1.00
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98
Cortical control of affective networks. J Neurosci (2013) 0.97
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Glutamate concentration in the medial prefrontal cortex predicts resting-state cortical-subcortical functional connectivity in humans. PLoS One (2013) 0.96
Relationships among cognition, emotion, and motivation: implications for intervention and neuroplasticity in psychopathology. Front Hum Neurosci (2013) 0.95
Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology (Berl) (2015) 0.95
Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord (2013) 0.95
New paradigms for treatment-resistant depression. Ann N Y Acad Sci (2013) 0.94
Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT (2012) 0.92
Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes. Eur Arch Psychiatry Clin Neurosci (2013) 0.90
Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res (2012) 0.89
Common and Dissociable Mechanisms of Executive System Dysfunction Across Psychiatric Disorders in Youth. Am J Psychiatry (2016) 0.87
Cortical-amygdalar circuit dysfunction in a genetic mouse model of serotonin deficiency. J Neurosci (2013) 0.87
Early life stress is associated with greater default network deactivation during working memory in healthy controls: a preliminary report. Brain Imaging Behav (2013) 0.84
Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord (2012) 0.84
The neuroscience of depression: implications for assessment and intervention. Behav Res Ther (2014) 0.83
Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder. Neuroimage (2015) 0.83
Multistage drug effects of ketamine in the treatment of major depression. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depress Anxiety (2016) 0.82
EEG power asymmetry and functional connectivity as a marker of treatment effectiveness in DBS surgery for depression. Neuropsychopharmacology (2013) 0.81
Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology (2014) 0.81
Cortical abnormalities and association with symptom dimensions across the depressive spectrum. J Affect Disord (2015) 0.80
Biomarker Development for Brain-Based Disorders: Recent Progress in Psychiatry. J Neurol Psychol (2013) 0.79
Differences in regional cerebral blood flow response to a 5HT3 antagonist in early- and late-onset cocaine-dependent subjects. Addict Biol (2012) 0.79
Psychiatric stress testing: novel strategy for translational psychopharmacology. Neuropsychopharmacology (2010) 0.79
Repeated acupuncture treatments modulate amygdala resting state functional connectivity of depressive patients. Neuroimage Clin (2016) 0.78
Species-conserved reconfigurations of brain network topology induced by ketamine. Transl Psychiatry (2016) 0.77
Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety (2011) 0.77
Structural connectivity and response to ketamine therapy in major depression: A preliminary study. J Affect Disord (2015) 0.76
Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine. Int J Neuropsychopharmacol (2015) 0.76
Dysregulation of Prefrontal Cortex-Mediated Slow-Evolving Limbic Dynamics Drives Stress-Induced Emotional Pathology. Neuron (2016) 0.75
Alterations of Intrinsic Brain Connectivity Patterns in Depression and Bipolar Disorders: A Critical Assessment of Magnetoencephalography-Based Evidence. Front Psychiatry (2017) 0.75
Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. Psychiatry Res (2016) 0.75
Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action. Behav Pharmacol (2017) 0.75
Resting-State Neurophysiological Abnormalities in Posttraumatic Stress Disorder: A Magnetoencephalography Study. Front Hum Neurosci (2017) 0.75
AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res (1996) 53.52
A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 36.40
Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage (2002) 29.63
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
On the practice of dichotomization of quantitative variables. Psychol Methods (2002) 9.18
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct (2008) 6.32
Dynamic imaging of coherent sources: Studying neural interactions in the human brain. Proc Natl Acad Sci U S A (2001) 5.45
Selective and divided attention during visual discriminations of shape, color, and speed: functional anatomy by positron emission tomography. J Neurosci (1991) 4.74
Cingulate function in depression: a potential predictor of treatment response. Neuroreport (1997) 4.48
The definition and meaning of treatment-resistant depression. J Clin Psychiatry (2001) 3.98
Neurobiological mechanisms of the placebo effect. J Neurosci (2005) 3.41
Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry (2004) 3.33
Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex (1999) 3.31
Signal processing in magnetoencephalography. Methods (2001) 3.20
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04
Cerebral correlates of autonomic cardiovascular arousal: a functional neuroimaging investigation in humans. J Physiol (2000) 2.72
Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci (2008) 2.35
Brain activity during transient sadness and happiness in healthy women. Am J Psychiatry (1995) 2.26
A new approach to neuroimaging with magnetoencephalography. Hum Brain Mapp (2005) 2.21
Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology (2005) 2.16
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry (2007) 2.15
Cognitive fitness of cost-efficient brain functional networks. Proc Natl Acad Sci U S A (2009) 2.07
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Targeted electrode-based modulation of neural circuits for depression. J Clin Invest (2009) 2.03
Cognitive control and brain resources in major depression: an fMRI study using the n-back task. Neuroimage (2005) 2.02
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Task-related changes in cortical synchronization are spatially coincident with the hemodynamic response. Neuroimage (2002) 1.68
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry (2008) 1.64
Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression. Biol Psychiatry (2003) 1.59
Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res (1999) 1.51
Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology (2007) 1.48
Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry (2007) 1.48
Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder. Mol Psychiatry (2006) 1.46
Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41
A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry (2007) 1.11
Limbic over-activity in depression during preserved performance on the n-back task. Neuroimage (2005) 1.02
Working-memory fMRI reveals cingulate hyperactivation in euthymic major depression. Hum Brain Mapp (2009) 0.99
Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry (2003) 6.93
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry (2003) 6.52
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology (2010) 5.07
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
Classical fear conditioning in the anxiety disorders: a meta-analysis. Behav Res Ther (2005) 3.83
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2007) 3.15
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci (2011) 2.76
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Families at high and low risk for depression: a 3-generation study. Arch Gen Psychiatry (2005) 2.62
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice. J Neurosci (2006) 2.40
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med (2009) 2.37
Overgeneralization of conditioned fear as a pathogenic marker of panic disorder. Am J Psychiatry (2009) 2.33
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Neuronal avalanches in the resting MEG of the human brain. J Neurosci (2013) 2.08
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychol Med (2005) 1.99
5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol (2009) 1.99
Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology (2003) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry (2002) 1.94
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
Generalization of conditioned fear-potentiated startle in humans: experimental validation and clinical relevance. Behav Res Ther (2008) 1.84
Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril (2007) 1.82
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test). Nat Protoc (2012) 1.75
Impaired discriminative fear-conditioning resulting from elevated fear responding to learned safety cues among individuals with panic disorder. Behav Res Ther (2008) 1.73
Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. J Neurosci (2008) 1.72
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol Psychiatry (2006) 1.71
Association of the SerCys DISC1 polymorphism with human hippocampal formation gray matter and function during memory encoding. Eur J Neurosci (2008) 1.67
Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry (2002) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Normal age-related brain morphometric changes: nonuniformity across cortical thickness, surface area and gray matter volume? Neurobiol Aging (2010) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Interactive effects of DAOA (G72) and catechol-O-methyltransferase on neurophysiology in prefrontal cortex. Biol Psychiatry (2011) 1.58
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry (2012) 1.55
Phasic and sustained fear in humans elicits distinct patterns of brain activity. Neuroimage (2010) 1.55
The adaptive threat bias in anxiety: amygdala-dorsomedial prefrontal cortex coupling and aversive amplification. Neuroimage (2011) 1.52
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
The effects of tryptophan depletion on neural responses to emotional words in remitted depression. Biol Psychiatry (2009) 1.50
Self-regulation of amygdala activation using real-time FMRI neurofeedback. PLoS One (2011) 1.50
Neural dynamics for facial threat processing as revealed by gamma band synchronization using MEG. Neuroimage (2006) 1.49
Interactive effect of apolipoprotein e genotype and age on hippocampal activation during memory processing in healthy adults. Arch Gen Psychiatry (2012) 1.48
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Match between cue and memory valence during autobiographical memory recall in depression. Psychol Rep (2012) 1.40
Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry (2011) 1.38
Cerebral blood flow in immediate and sustained anxiety. J Neurosci (2007) 1.38
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
Neural basis of abnormal response to negative feedback in unmedicated mood disorders. Neuroimage (2008) 1.37
Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry (2005) 1.37
Contextual-specificity of short-delay extinction in humans: renewal of fear-potentiated startle in a virtual environment. Learn Mem (2007) 1.36
Neural responses to auditory stimulus deviance under threat of electric shock revealed by spatially-filtered magnetoencephalography. Neuroimage (2007) 1.36
Emotional automaticity is a matter of timing. J Neurosci (2010) 1.35
The strong situation: a potential impediment to studying the psychobiology and pharmacology of anxiety disorders. Biol Psychol (2005) 1.33
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Startle response in behaviorally inhibited adolescents with a lifetime occurrence of anxiety disorders. J Am Acad Child Adolesc Psychiatry (2009) 1.32